Return to Results

Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS II

new search

Trial Conditions
  • Lung Cancer
What is the purpose of this trial?

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

Date & Status

Active, not recruiting

Who can Participate?


21 and older



Inclusion Criteria:

- Patients being evaluated for the diagnosis of possible lung cancer or "rule out lung
cancer" and undergoing clinically indicated bronchoscopy

- All patients are required to be at least 21 years of age and be able to understand
and sign the informed consent form

- Patient must be a current or former cigarette smoker

Exclusion Criteria:

- A pulmonary physician does not recommend that bronchoscopy be performed

- Inability to understand the written consent form and comply with requirements of the

- History of prior primary lung cancer

- Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator
for >24 consecutive hours.

Gender: Both
Steward Physician(s)
  • Duncan Whitney, PhD
Trial Interventions
  • Biomarker (not used as an intervention)
Physician Researcher

Investigator Name:

  • Duncan Whitney, PhD

Other Information

Sponsor: Allegro Diagnostics, Corp.
Phase: N/A
Trial ID: NCT00746759
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions